The aim of this proposal is to better understand the proportion of mononuclear phagocytes that are infected with Human Immunodeficiency Virus (HIV) in patients infected with HIV and the consequences of such infection on the function of this cell. The goal will be to provide information that will be useful for therapy directed at inhibiting HIV replication in macrophages and correcting immune defects which are a consequences of infection with HIV. There is increasing evidence that macrophages are infected with HIV, can be a reservoir for infection of other cells, and may be the cell which helps to transport HIV into the central nervous system. Hence, strategies to develop new agents active against HIV must take into account the possibility that a significant proportion of the virus in a patient may reside in mononuclear phagocytes. These agents must be able to penetrate into this cell and correct any functional defects induced by HIV. Therefore, we will attempt to determine the proportion of monocytes and tissue macrophages that are infected in patients infected with HIV who have a spectrum of clinical illness ranging from asymptomatic to AIDS. Both immunofluorescent antibody and in situ techniques will be used. We will infect human monocyte derived macrophages (mo) with strains of HIV isolated from peripheral blood mononuclear cells, brain tissue and pulmonary mo. The latter two sources may yield HIV isolates which will more efficiently infect mo. We will also infect the monocyte cell line U-937 with HIV. We will then examine mo functions with knowledge of the proportion of cells that are infected with HIV. The functions to be studied include phagocytosis, killing of facultative intracellular bacteria and protozoa, oxidative burst, phagosomelysosome fusion, production of IL-1, and antigen processing. The effect of new agents developed by other members of this cooperative group, as well as 3'-Azido-3'-deoxythymidine (AZT) will be tested for their effect on HIV infection of mononuclear phagocytes and correction of functional defects induced by HIV.

Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
1990
Total Cost
Indirect Cost
Name
State University New York Stony Brook
Department
Type
DUNS #
804878247
City
Stony Brook
State
NY
Country
United States
Zip Code
11794
Morrison, S A; Pearson, S L; Steigbigel, R T (1998) Anti-F(ab')2 antibody in HIV type 1 infection: relationship to hypergammaglobulinemia and to antibody specific to the V3 loop region of glycoprotein 120. AIDS Res Hum Retroviruses 14:491-8
Moorjani, H; Craddock, B P; Morrison, S A et al. (1996) Impairment of phagosome-lysosome fusion in HIV-1-infected macrophages. J Acquir Immune Defic Syndr Hum Retrovirol 13:18-22
Handley, M A; Steigbigel, R T; Morrison, S A (1996) A role for urokinase-type plasminogen activator in human immunodeficiency virus type 1 infection of macrophages. J Virol 70:4451-6
Maruenda, H; Johnson, F (1995) Design and synthesis of novel inhibitors of HIV-1 reverse transcriptase. J Med Chem 38:2145-51
Tyagi, S C; Simon, S R; Carter, C A (1994) Effect of pH and nonphysiological salt concentrations on human immunodeficiency virus-1 protease dimerization. Biochem Cell Biol 72:175-81
Zybarth, G; Krausslich, H G; Partin, K et al. (1994) Proteolytic activity of novel human immunodeficiency virus type 1 proteinase proteins from a precursor with a blocking mutation at the N terminus of the PR domain. J Virol 68:240-50
Carter, C; Zybarth, G (1994) Processing of retroviral Gag polyproteins: an in vitro approach. Methods Enzymol 241:227-53
Ehrlich, L S; Agresta, B E; Gelfand, C A et al. (1994) Spectral analysis and tryptic susceptibility as probes of HIV-1 capsid protein structure. Virology 204:515-25
Suzuki, K; Craddock, B P; Kano, T et al. (1993) Colorimetric reverse transcriptase assay for HIV-1. J Virol Methods 41:21-8
Tyagi, S C (1992) Inhibitors of human immunodeficiency virus-1 protease. Biochem Cell Biol 70:309-15

Showing the most recent 10 out of 23 publications